Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12247426 | 0.88 | HTT (0.58) | HTTSMN1; SMN2RAB9AKMT2AMEN1 | |
| SCHEMBL21879981 | 0.85 | RAB9A (0.46) | HTTSMN1; SMN2RAB9AKMT2AMEN1 | |
| SCHEMBL10579577 | 0.75 | SMN1; SMN2 (0.52) | SMN1; SMN2RAB9AKMT2AMEN1NPC1 | |
| SCHEMBL8700542 | 0.74 | SMN1; SMN2 (0.48) | SMN1; SMN2RAB9AKMT2AMEN1NPC1 | |
| SCHEMBL6344541 | 0.74 | SMN1; SMN2 (0.48) | HTTSMN1; SMN2RAB9AKMT2AMEN1 | |
| SCHEMBL2228123 | 0.74 | SMN1; SMN2 (0.48) | SMN1; SMN2RAB9AKMT2AMEN1NPC1 | |
| SCHEMBL8081105 | 0.74 | SMN1; SMN2 (0.48) | SMN1; SMN2RAB9AKMT2AMEN1NPC1 | |
| SCHEMBL23421998 | 0.73 | SMN1; SMN2 (0.45) | HTTSMN1; SMN2RAB9AKMT2AMEN1 | |
| SCHEMBL17604235 | 0.73 | HTT (0.43) | HTTSMN1; SMN2RAB9AKMT2AMEN1 | |
| SCHEMBL21879941 | 0.72 | SMN1; SMN2 (0.47) | HTTSMN1; SMN2RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12065430-B2 | Indazole compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-08-20 | — | — | US | disclosed |
| EP-3871673-B1 | NOVEL INDAZOLE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2024-01-03 | — | — | EP | disclosed |
| US-20230181536-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-06-15 | — | — | US | disclosed |
| US-20210395234-A1 | NOVEL INDAZOLE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO. LTD. (JP) | 2021-12-23 | — | — | US | disclosed |
| WO-2021215545-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-10-28 | — | — | WO | disclosed |
| WO-2020085493-A1 | NOVEL INDAZOLE COMPOUND OR SALT THEREOF | 大鵬薬品工業株式会社 | 2020-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12065430-B2 | Indazole compound or salt thereof | RCOR3, H1-3, BICRA | HTT 2899/4885SMN1; SMN2 3985/4885RAB9A 534/4885 |
| US-20230181536-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | KRAS, NRAS, HRAS | HTT 2313/4885SMN1; SMN2 384/4885RAB9A 82/4885 |
| US-20210395234-A1 | NOVEL INDAZOLE COMPOUND OR SALT THEREOF | HDAC11, RCOR3, BICRA | HTT 3401/4885SMN1; SMN2 3903/4885RAB9A 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.